Baidu
map

内分泌科指南

订阅

MedSci主页 / 所有栏目 / 内分泌科指南

2020 专家声明：斋月期间应用SGLT2抑制剂

2020-09-21 国外内分泌相关专家小组（统称） Diabetes Res Clin Pract . 2020 Sep 21;

SGLT2抑制剂

斋月期间斋戒在糖尿病的管理中占有重要地位，本文由12位专家共同商讨而成，主要针对斋月期间应用SGLT2抑制剂的相关内容提供共识意见。

中文标题：

2020 专家声明：斋月期间应用SGLT2抑制剂

英文标题：

Use of SGLT2 Inhibitors During Ramadan: An Expert Panel Statement

发布机构：

国外内分泌相关专家小组（统称）

发布日期：

2020-09-21

简要介绍：

斋月期间斋戒在糖尿病的管理中占有重要地位，本文由12位专家共同商讨而成，主要针对斋月期间应用SGLT2抑制剂的相关内容提供共识意见。

相关资料下载：
[AttachmentFileName(sort=1, fileName=2020 专家声明：斋月期间应用SGLT2抑制剂.pdf)] GetToolGuiderByIdResponse(projectId=1, id=e2c251c00198965b, title=2020 专家声明：斋月期间应用SGLT2抑制剂, enTitle=Use of SGLT2 Inhibitors During Ramadan: An Expert Panel Statement, guiderFrom=Diabetes Res Clin Pract . 2020 Sep 21;, authorId=0, author=, summary=斋月期间斋戒在糖尿病的管理中占有重要地位，本文由12位专家共同商讨而成，主要针对斋月期间应用SGLT2抑制剂的相关内容提供共识意见。, cover=https://img.medsci.cn/20201014/1602607830236_2020535.jpg, journalId=0, articlesId=null, associationId=949, associationName=国外内分泌相关专家小组（统称）, associationIntro=null, copyright=0, guiderPublishedTime=Mon Sep 21 00:00:00 CST 2020, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #373737;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>斋月期间斋戒在糖尿病的管理中占有重要地位，本文由12位专家共同商讨而成，主要针对斋月期间应用SGLT2抑制剂的相关内容提供共识意见。</p> </div> </div> </div>, tagList=[TagDto(tagId=20298, tagName=SGLT2抑制剂)], categoryList=[CategoryDto(categoryId=6, categoryName=内分泌科, tenant=100), CategoryDto(categoryId=8, categoryName=糖尿病, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=20298, guiderKeyword=SGLT2抑制剂, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=4, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=9309, appHits=106, showAppHits=0, pcHits=508, showPcHits=9203, likes=0, shares=9, comments=6, approvalStatus=1, publishedTime=Wed Oct 14 01:20:55 CST 2020, publishedTimeString=2020-09-21, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=qiushida2, createdTime=Wed Oct 14 00:50:39 CST 2020, updatedBy=2020535, updatedName=qiushida2, updatedTime=Sat Jan 06 11:20:18 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2020 专家声明：斋月期间应用SGLT2抑制剂.pdf)])
2020 专家声明：斋月期间应用SGLT2抑制剂.pdf
下载请点击：
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=894902, encodeId=3bc48949027b, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d095409783, createdName=ms5000002046462755, createdTime=Tue Oct 27 19:14:02 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894588, encodeId=44568945888a, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=72fa2381620, createdName=12314969m72暂无昵称, createdTime=Mon Oct 26 18:24:16 CST 2020, time=2020-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=892148, encodeId=a20289214838, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200808/1cb8d8920798424db282492ee59f6942/e0c7c0fac61e4530ab09e7708f7963bb.jpg, createdBy=08f62038950, createdName=1861e93c24m, createdTime=Wed Oct 14 23:29:55 CST 2020, time=2020-10-14, status=1, ipAttribution=)]
    2020-10-27 ms5000002046462755

    好

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=894902, encodeId=3bc48949027b, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d095409783, createdName=ms5000002046462755, createdTime=Tue Oct 27 19:14:02 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894588, encodeId=44568945888a, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=72fa2381620, createdName=12314969m72暂无昵称, createdTime=Mon Oct 26 18:24:16 CST 2020, time=2020-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=892148, encodeId=a20289214838, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200808/1cb8d8920798424db282492ee59f6942/e0c7c0fac61e4530ab09e7708f7963bb.jpg, createdBy=08f62038950, createdName=1861e93c24m, createdTime=Wed Oct 14 23:29:55 CST 2020, time=2020-10-14, status=1, ipAttribution=)]
    2020-10-26 12314969m72暂无昵称

    谢谢

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=894902, encodeId=3bc48949027b, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d095409783, createdName=ms5000002046462755, createdTime=Tue Oct 27 19:14:02 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894588, encodeId=44568945888a, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=72fa2381620, createdName=12314969m72暂无昵称, createdTime=Mon Oct 26 18:24:16 CST 2020, time=2020-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=892148, encodeId=a20289214838, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200808/1cb8d8920798424db282492ee59f6942/e0c7c0fac61e4530ab09e7708f7963bb.jpg, createdBy=08f62038950, createdName=1861e93c24m, createdTime=Wed Oct 14 23:29:55 CST 2020, time=2020-10-14, status=1, ipAttribution=)]
    2020-10-14 1861e93c24m

    学习

    0

拓展阅读

心力衰竭SGLT2抑制剂临床应用的中国专家共识

中国心力衰竭中心联盟专家委员会 · 2022-07-07

2022 CCS指南：应用GLP-1受体激动剂和SGLT2 抑制剂降低成人心肾风险

加拿大心血管学会(CCS,Canadian Cardiovascular Society) · 2022-08-10

新加坡专家共识声明：亚太国家使用 SGLT-2 抑制剂的实际考虑

新加坡肾和移植相关专家小组（统称） · 2023-05-08

Baidu
map
Baidu
map
Baidu
map